Thursday, March 10, 2011

Sangamo HIV project could rewrite story of state's stem cell agency

A consortium that includes Sangamo BioSciences Inc. is pursuing a next-generation stem cell treatment that could provide a longer-term — if not lifetime — barrier to the AIDS virus.
But the fate of California's $3 billion stem cell research funding agency also may rest on the success or failure of the Sangamo collaboration and 13 other "disease teams" that are trying to get into clinical trials within four years.

No comments:

Post a Comment

Post a Comment